{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:55:52Z","timestamp":1775109352668,"version":"3.50.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. U24A20654"],"award-info":[{"award-number":["No. U24A20654"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170602"],"award-info":[{"award-number":["82170602"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40121-026-01321-8","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:00:41Z","timestamp":1773320441000},"page":"959-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"He-ming","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-qin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-6706","authenticated-orcid":false,"given":"Yan-hang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"47","key":"1321_CR1","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.3748\/wjg.v27.i47.8081","volume":"27","author":"R Gonz\u00e1lez Grande","year":"2021","unstructured":"Gonz\u00e1lez Grande R, Santaella Leiva I, L\u00f3pez Ortega S, Jim\u00e9nez P\u00e9rez M. Present and future management of viral hepatitis. World J Gastroenterol. 2021;27(47):8081\u2013102.","journal-title":"World J Gastroenterol"},{"key":"1321_CR2","unstructured":"Organization WH. Global hepatitis report 2024: action for access in low- and middle-income countries. [2024-04-09] https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"issue":"2","key":"1321_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","volume":"4","author":"GS Cooke","year":"2019","unstructured":"Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135\u201384.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1321_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","volume":"8","author":"F Cui","year":"2023","unstructured":"Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332\u201342.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1321_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010213","author":"HW Lee","year":"2020","unstructured":"Lee HW, Lee JS, Ahn SH. Hepatitis B virus cure: targets and future therapies. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms22010213.","journal-title":"Int J Mol Sci"},{"key":"1321_CR6","doi-asserted-by":"crossref","unstructured":"Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2).","DOI":"10.1128\/CMR.00046-19"},{"issue":"8","key":"1321_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1321_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092023","author":"B Jiang","year":"2020","unstructured":"Jiang B, Hildt E. Intracellular trafficking of HBV particles. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9092023.","journal-title":"Cells"},{"issue":"1","key":"1321_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3748\/wjg.v13.i1.39","volume":"13","author":"M Kann","year":"2007","unstructured":"Kann M, Schmitz A, Rabe B. Intracellular transport of hepatitis B virus. World J Gastroenterol. 2007;13(1):39\u201347.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1321_CR10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/HEP.0000000000000428","volume":"78","author":"DB Kum","year":"2023","unstructured":"Kum DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, Verrier ER, Baumert TF, et al. Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation. Hepatology (Baltimore, MD). 2023;78(4):1252\u201365.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"1321_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106446","volume":"90","author":"M Zhang","year":"2025","unstructured":"Zhang M, Gao Y, Kong F, Gao H, Yi Y, Wu C, et al. Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: a multicenter clinical trial. J Infect. 2025;90(3):106446.","journal-title":"J Infect"},{"issue":"1","key":"1321_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16213","volume":"45","author":"X Li","year":"2025","unstructured":"Li X, Xu J, Sun J, Liu J, Wu M, Zhang H, et al. Safety, pharmacokinetics and antiviral efficacy of capsid assembly modulator freethiadine in healthy volunteers and chronic hepatitis B patients. Liver Int. 2025;45(1):e16213.","journal-title":"Liver Int"},{"issue":"2","key":"1321_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","volume":"5","author":"MF Yuen","year":"2020","unstructured":"Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, et al. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020;5(2):152\u201366.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1321_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2022.05.027","volume":"77","author":"MS Sulkowski","year":"2022","unstructured":"Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, et al. Safety and efficacy of vebicorvir administered with entecavir in treatment-na\u00efve patients with chronic hepatitis B virus infection. J Hepatol. 2022;77(5):1265\u201375.","journal-title":"J Hepatol"},{"key":"1321_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105715","volume":"218","author":"J Xi","year":"2023","unstructured":"Xi J, Gu Z, Sun C, Chen Z, Zhang T, Chen R, et al. A novel hepatitis B virus capsid assembly modulator QL-007 inhibits HBV replication and infection through altering capsid assembly. Antiviral Res. 2023;218:105715.","journal-title":"Antiviral Res"},{"key":"1321_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103400","volume":"87","author":"C Wang","year":"2025","unstructured":"Wang C, Kong F, Gao H, Cai D, Zhang G, Ning Q, et al. Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study. EClinicalMedicine. 2025;87:103400.","journal-title":"EClinicalMedicine"},{"issue":"23","key":"1321_CR17","doi-asserted-by":"publisher","first-page":"21126","DOI":"10.1021\/acs.jmedchem.4c01814","volume":"67","author":"S Vendeville","year":"2024","unstructured":"Vendeville S, Amblard F, Bassit L, Beigelman LN, Blatt LM, Chen X, et al. The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075. J Med Chem. 2024;67(23):21126\u201342.","journal-title":"J Med Chem"},{"issue":"9","key":"1321_CR18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/17460441.2023.2239701","volume":"18","author":"L Bassit","year":"2023","unstructured":"Bassit L, Amblard F, Patel D, Biteau N, Chen Z, Kasthuri M, et al. The premise of capsid assembly modulators towards eliminating HBV persistence. Expert Opin Drug Discov. 2023;18(9):1031\u201341.","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"1321_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3350\/cmh.2023.0535","volume":"30","author":"MF Yuen","year":"2024","unstructured":"Yuen MF, Chuang WL, Peng CY, Jeng WJ, Su WW, Chang TT, et al. Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients. Clin Mol Hepatol. 2024;30(3):375\u201387.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"1321_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-03004-3","volume":"22","author":"L Nguyen","year":"2024","unstructured":"Nguyen L, Nguyen TT, Kim JY, Jeong JH. Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates. J Nanobiotechnol. 2024;22(1):745.","journal-title":"J Nanobiotechnol"},{"issue":"9","key":"1321_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"MF Yuen","year":"2023","unstructured":"Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(9):790\u2013802.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1321_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","volume":"81","author":"K Agarwal","year":"2024","unstructured":"Agarwal K, Buti M, van B\u00f6mmel F, Lampertico P, Janczewska E, Bourliere M, et al. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. J Hepatol. 2024;81(3):404\u201314.","journal-title":"J Hepatol"},{"issue":"12","key":"1321_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","volume":"9","author":"MF Yuen","year":"2024","unstructured":"Yuen MF, Lim YS, Yoon KT, Lim TH, Heo J, Tangkijvanich P, et al. VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. Lancet Gastroenterol Hepatol. 2024;9(12):1121\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"1321_CR24","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1021\/acsinfecdis.4c00514","volume":"10","author":"EP Thi","year":"2024","unstructured":"Thi EP, Ye X, Snead NM, Lee ACH, Micolochick Steuer HM, Ardzinski A, et al. Control of hepatitis B virus with Imdusiran, a small interfering RNA therapeutic. ACS Infect Dis. 2024;10(10):3640\u20139.","journal-title":"ACS Infect Dis"},{"issue":"11","key":"1321_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31924","volume":"10","author":"Q Li","year":"2024","unstructured":"Li Q, Geng T, Li H, Zheng S, Svedlund S, Gan L, et al. Analysis of the pharmacokinetics and efficacy of RBD1016\u2014a GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK\/PD model. Heliyon. 2024;10(11):e31924.","journal-title":"Heliyon"},{"issue":"22","key":"1321_CR26","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","volume":"391","author":"J Hou","year":"2024","unstructured":"Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado LE, et al. Xalnesiran with or without an immunomodulator in chronic hepatitis B. N Engl J Med. 2024;391(22):2098\u2013109.","journal-title":"N Engl J Med"},{"issue":"1","key":"1321_CR27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21505594.2022.2093444","volume":"13","author":"S Phillips","year":"2022","unstructured":"Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for chronic hepatitis B. Virulence. 2022;13(1):1111\u201332.","journal-title":"Virulence"},{"issue":"21","key":"1321_CR28","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, et al. Efficacy and safety of Bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387(21):1957\u201368.","journal-title":"N Engl J Med"},{"issue":"4","key":"1321_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","volume":"77","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol. 2022;77(4):967\u201377.","journal-title":"J Hepatol"},{"issue":"4","key":"1321_CR30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","volume":"79","author":"E Gane","year":"2023","unstructured":"Gane E, Lim YS, Kim JB, Jadhav V, Shen L, Bakardjiev AI, et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials. J Hepatol. 2023;79(4):924\u201332.","journal-title":"J Hepatol"},{"issue":"3","key":"1321_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","volume":"65","author":"A Blank","year":"2016","unstructured":"Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65(3):483\u20139.","journal-title":"J Hepatol"},{"issue":"1","key":"1321_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","volume":"23","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer H, Sch\u00f6neweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023;23(1):117\u201329.","journal-title":"Lancet Infect Dis"},{"key":"1321_CR33","doi-asserted-by":"publisher","first-page":"110053","DOI":"10.1016\/j.biopha.2020.110053","volume":"126","author":"XJ Liu","year":"2020","unstructured":"Liu XJ, Liu C, Zhu LY, Fan CL, Niu C, Liu XP, et al. Hepalatide ameliorated progression of nonalcoholic steatohepatitis in mice. Biomed Pharmacother. 2020;126:110053.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1321_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/hep.32614","volume":"77","author":"C Xu","year":"2023","unstructured":"Xu C, Fan J, Liu D, Tuerdi A, Chen J, Wei Y, et al. Alpha-kinase 1 (ALPK1) agonist DF-006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B. Hepatology (Baltimore, MD). 2023;77(1):275\u201389.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"1321_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/liv.15465","volume":"43","author":"MF Yuen","year":"2023","unstructured":"Yuen MF, Chen CY, Liu CJ, Jeng WJ, Elkhashab M, Coffin CS, et al. A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-na\u00efve patients with chronic hepatitis B. Liver Int. 2023;43(1):77\u201389.","journal-title":"Liver Int"},{"issue":"12","key":"1321_CR36","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/jvh.13608","volume":"28","author":"R Erken","year":"2021","unstructured":"Erken R, Andre P, Roy E, Kootstra N, Barzic N, Girma H, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study. J Viral Hepatitis. 2021;28(12):1690\u20138.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"1321_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23525-w","volume":"8","author":"J Lucifora","year":"2018","unstructured":"Lucifora J, Bonnin M, Aillot L, Fusil F, Maadadi S, Dimier L, et al. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Sci Rep. 2018;8(1):5390.","journal-title":"Sci Rep"},{"issue":"4","key":"1321_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1473-3099(22)00727-7","volume":"23","author":"MF Yuen","year":"2023","unstructured":"Yuen MF, Balabanska R, Cottreel E, Chen E, Duan D, Jiang Q, et al. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2023;23(4):496\u2013507.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1321_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jhep.2022.09.027","volume":"78","author":"EJ Gane","year":"2023","unstructured":"Gane EJ, Dunbar PR, Brooks AE, Zhang F, Chen D, Wallin JJ, et al. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression. J Hepatol. 2023;78(3):513\u201323.","journal-title":"J Hepatol"},{"issue":"1","key":"1321_CR40","doi-asserted-by":"publisher","first-page":"12767","DOI":"10.1038\/s41598-020-69614-7","volume":"10","author":"V Janovec","year":"2020","unstructured":"Janovec V, Hodek J, Clarova K, Hofman T, Dostalik P, Fronek J, et al. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Sci Rep. 2020;10(1):12767.","journal-title":"Sci Rep"},{"issue":"1","key":"1321_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","volume":"82","author":"HC Mon","year":"2025","unstructured":"Mon HC, Lee PC, Hung YP, Hung YW, Wu CJ, Lee CJ, et al. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J Hepatol. 2025;82(1):51\u201361.","journal-title":"J Hepatol"},{"issue":"2","key":"1321_CR42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40265-022-01671-w","volume":"82","author":"A Markham","year":"2022","unstructured":"Markham A. Envafolimab: first approval. Drugs. 2022;82(2):235\u201340.","journal-title":"Drugs"},{"issue":"3","key":"1321_CR43","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/liv.12530","volume":"35","author":"SK Yoon","year":"2015","unstructured":"Yoon SK, Seo YB, Im SJ, Bae SH, Song MJ, You CR, et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int. 2015;35(3):805\u201315.","journal-title":"Liver Int"},{"key":"1321_CR44","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.02.016","author":"Y Ji","year":"2025","unstructured":"Ji Y, Le Bert N, Lai-Hung Wong G, Douglas MW, Lee A, Zhu C, et al. The impact of hepatitis B surface antigen reduction via small interfering RNA treatment on natural and vaccine (BRII-179)-induced hepatitis B virus-specific humoral and cellular immune responses. Gastroenterology. 2025. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.016.","journal-title":"Gastroenterology"},{"issue":"6","key":"1321_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100361","volume":"3","author":"H Ma","year":"2021","unstructured":"Ma H, Lim TH, Leerapun A, Weltman M, Jia J, Lim YS, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study. JHEP Rep. 2021;3(6):100361.","journal-title":"JHEP Rep"},{"issue":"1","key":"1321_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","volume":"157","author":"C Boni","year":"2019","unstructured":"Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology. 2019;157(1):227-41.e7.","journal-title":"Gastroenterology"},{"issue":"6","key":"1321_CR47","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","volume":"81","author":"WY Tak","year":"2024","unstructured":"Tak WY, Chuang WL, Chen CY, Tseng KC, Lim YS, Lo GH, et al. Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB. J Hepatol. 2024;81(6):949\u201359.","journal-title":"J Hepatol"},{"issue":"13","key":"1321_CR48","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","volume":"18","author":"HW Lee","year":"2020","unstructured":"Lee HW, Park JY, Hong T, Park MS, Ahn SH. Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2020;18(13):3043-5.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1321_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101360","volume":"63","author":"N Nasser","year":"2023","unstructured":"Nasser N, Tonnerre P, Mansouri A, Asselah T. Hepatitis-B virus: replication cycle, targets, and antiviral approaches. Curr Opin Virol. 2023;63:101360.","journal-title":"Curr Opin Virol"},{"issue":"8","key":"1321_CR50","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","volume":"158","author":"M Bazinet","year":"2020","unstructured":"Bazinet M, P\u00e2ntea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180\u201394.","journal-title":"Gastroenterology"},{"issue":"5","key":"1321_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00094-22","volume":"66","author":"X Li","year":"2022","unstructured":"Li X, Liu Y, Yao H, Wang M, Gao L, Lou J, et al. Safety, tolerability, and pharmacokinetics of the novel hepatitis B virus expression inhibitor GST-HG131 in healthy Chinese subjects: a first-in-human single- and multiple-dose escalation trial. Antimicrob Agents Chemother. 2022;66(5):e0009422.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1321_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097579","volume":"9","author":"ND Weber","year":"2014","unstructured":"Weber ND, Stone D, Sedlak RH, De Silva Feelixge HS, Roychoudhury P, Schiffer JT, et al. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS ONE. 2014;9(5):e97579.","journal-title":"PLoS ONE"},{"key":"1321_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/v13071344","author":"T Smith","year":"2021","unstructured":"Smith T, Singh P, Chmielewski KO, Bloom K, Cathomen T, Arbuthnot P, et al. Improved specificity and safety of anti-hepatitis B virus TALENs using obligate heterodimeric FokI nuclease domains. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13071344.","journal-title":"Viruses"},{"issue":"5","key":"1321_CR54","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/HEP.0000000000000642","volume":"79","author":"RG Gish","year":"2024","unstructured":"Gish RG, Wong RJ, Di Tanna GL, Kaushik A, Kim C, Smith NJ, et al. Association of hepatitis delta virus with liver morbidity and mortality: a systematic literature review and meta-analysis. Hepatology (Baltimore, MD). 2024;79(5):1129\u201340.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"12","key":"1321_CR55","volume":"2011","author":"Z Abbas","year":"2011","unstructured":"Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev. 2011;2011(12):Cd006002.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1321_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70008","volume":"45","author":"P Lampertico","year":"2025","unstructured":"Lampertico P, Bogomolov PO, Chulanov V, Stepanova T, Morozov V, Allweiss L, et al. Phase 2 randomised study of bulevirtide as monotherapy or combined with Peg-IFN\u03b1-2a as treatment for chronic hepatitis delta. Liver Int. 2025;45(2):e70008.","journal-title":"Liver Int"},{"issue":"2","key":"1321_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.5152\/tjg.2020.18846","volume":"31","author":"Z Abbas","year":"2020","unstructured":"Abbas Z, Saad M, Asim M, Abbas M, Samejo SA. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D. Turk J Gastroenterol. 2020;31(2):136\u201341.","journal-title":"Turk J Gastroenterol"},{"issue":"10","key":"1321_CR58","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15(10):1167\u201374.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"1321_CR59","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/hep.32259","volume":"75","author":"C Yurdaydin","year":"2022","unstructured":"Yurdaydin C, Keskin O, Yurdcu E, \u00c7ali\u015fkan A, \u00d6nem S, Karakaya F, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology (Baltimore, MD). 2022;75(6):1551\u201365.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"1321_CR60","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hep4.1633","volume":"5","author":"M Bazinet","year":"2021","unstructured":"Bazinet M, P\u00e2ntea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis b virus\/hepatitis delta virus coinfection. Hepatol Commun. 2021;5(2):189\u2013202.","journal-title":"Hepatol Commun"},{"issue":"6","key":"1321_CR61","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580\u201393.","journal-title":"N Engl J Med"},{"key":"1321_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/v13010041","author":"MA Martinez","year":"2020","unstructured":"Martinez MA, Franco S. Therapy implications of hepatitis C virus genetic diversity. Viruses. 2020. https:\/\/doi.org\/10.3390\/v13010041.","journal-title":"Viruses"},{"key":"1321_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/v16111739","author":"M Fasano","year":"2024","unstructured":"Fasano M, Ieva F, Ciarallo M, Caccianotti B, Santantonio TA. Acute hepatitis C: current status and future perspectives. Viruses. 2024. https:\/\/doi.org\/10.3390\/v16111739.","journal-title":"Viruses"},{"key":"1321_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/v17020163","author":"L Di Marco","year":"2025","unstructured":"Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, Mantia C, et al. A comprehensive review of antiviral therapy for hepatitis C: the long journey from interferon to pan-genotypic direct-acting antivirals (DAAs). Viruses. 2025. https:\/\/doi.org\/10.3390\/v17020163.","journal-title":"Viruses"},{"issue":"38","key":"1321_CR65","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.3748\/wjg.v24.i38.4330","volume":"24","author":"D Omran","year":"2018","unstructured":"Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, et al. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol. 2018;24(38):4330\u201340.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1321_CR66","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S1473-3099(24)00307-4","volume":"24","author":"T Burki","year":"2024","unstructured":"Burki T. WHO\u2019s 2024 global hepatitis report. Lancet Infect Dis. 2024;24(6):e362\u20133.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1321_CR67","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14787210.2024.2328336","volume":"22","author":"N Schiano Moriello","year":"2024","unstructured":"Schiano Moriello N, Pinchera B, Gentile I. Personalized care approaches to hepatitis C therapy: recent advances and future directions. Expert Rev Anti-infect Ther. 2024;22(4):139\u201351.","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"1","key":"1321_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/13543784.2024.2305137","volume":"33","author":"XJ Zhou","year":"2024","unstructured":"Zhou XJ, Good SS, Pietropaolo K, Huang Q, Moussa A, Hammond JM, et al. Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase. Expert Opin Investig Drugs. 2024;33(1):9\u201317.","journal-title":"Expert Opin Investig Drugs"},{"key":"1321_CR69","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-19","author":"E Berliba","year":"2019","unstructured":"Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, et al. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.01201-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1321_CR70","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/infdis\/jir399","volume":"204","author":"Z Stamataki","year":"2011","unstructured":"Stamataki Z, Coates S, Abrignani S, Houghton M, McKeating JA. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis. 2011;204(5):811\u20133.","journal-title":"J Infect Dis"},{"key":"1321_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/v16081337","author":"AR Garbuglia","year":"2024","unstructured":"Garbuglia AR, Pauciullo S, Zulian V, Del Porto P. Update on hepatitis C vaccine: results and challenges. Viruses. 2024. https:\/\/doi.org\/10.3390\/v16081337.","journal-title":"Viruses"},{"issue":"6","key":"1321_CR72","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJMoa2023345","volume":"384","author":"K Page","year":"2021","unstructured":"Page K, Melia MT, Veenhuis RT, Winter M, Rousseau KE, Massaccesi G, et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med. 2021;384(6):541\u20139.","journal-title":"N Engl J Med"},{"key":"1321_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/v15051080","author":"F Gabrielli","year":"2023","unstructured":"Gabrielli F, Alberti F, Russo C, Cursaro C, Seferi H, Margotti M, et al. Treatment options for hepatitis A and E: a non-systematic review. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15051080.","journal-title":"Viruses"},{"key":"1321_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/v13101900","author":"M Migueres","year":"2021","unstructured":"Migueres M, Lhomme S, Izopet J. Hepatitis A: epidemiology, high-risk groups, prevention and research on antiviral treatment. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13101900.","journal-title":"Viruses"},{"issue":"14","key":"1321_CR75","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3748\/wjg.v28.i14.1405","volume":"28","author":"MA Odenwald","year":"2022","unstructured":"Odenwald MA, Paul S. Viral hepatitis: past, present, and future. World J Gastroenterol. 2022;28(14):1405\u201329.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1321_CR76","first-page":"94","volume":"317","author":"JM Crance","year":"1994","unstructured":"Crance JM, Deloince R, Leveque F, Jouan A, Tr\u00e9po C. [Antiviral effect of recombinant interferon-alpha on hepatitis A virus replication in human liver cells]. C R Acad Sci. 1994;317(1):94\u20137.","journal-title":"C R Acad Sci"},{"key":"1321_CR77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.antiviral.2018.04.007","volume":"154","author":"W Jiang","year":"2018","unstructured":"Jiang W, Muhammad F, Ma P, Liu X, Long G. Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system. Antiviral Res. 2018;154:51\u20137.","journal-title":"Antiviral Res"},{"issue":"4","key":"1321_CR78","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1872-034X.2010.00617.x","volume":"40","author":"T Kanda","year":"2010","unstructured":"Kanda T, Imazeki F, Nakamoto S, Okitsu K, Fujiwara K, Yokosuka O. Internal ribosomal entry-site activities of clinical isolate-derived hepatitis A virus and inhibitory effects of amantadine. Hepatol Res. 2010;40(4):415\u201323.","journal-title":"Hepatol Res"},{"issue":"7","key":"1321_CR79","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/jvh.12873","volume":"25","author":"HM Zakaria","year":"2018","unstructured":"Zakaria HM, Salem TA, El-Araby HA, Salama RM, Elbadry DY, Sira AM, et al. Steroid therapy in children with fulminant hepatitis A. J Viral Hepatitis. 2018;25(7):853\u20139.","journal-title":"J Viral Hepatitis"},{"issue":"28","key":"1321_CR80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204511119","volume":"119","author":"Y Li","year":"2022","unstructured":"Li Y, Misumi I, Shiota T, Sun L, Lenarcic EM, Kim H, et al. The ZCCHC14\/TENT4 complex is required for hepatitis A virus RNA synthesis. Proc Natl Acad Sci USA. 2022;119(28):e2204511119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"1321_CR81","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMc1504302","volume":"372","author":"J Zhang","year":"2015","unstructured":"Zhang J, Shih JW, Xia NS. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372(23):2265\u20136.","journal-title":"N Engl J Med"},{"key":"1321_CR82","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256\u201371.","DOI":"10.1016\/j.jhep.2018.03.005"},{"issue":"2","key":"1321_CR83","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jvh.13432","volume":"28","author":"MB Mulder","year":"2021","unstructured":"Mulder MB, de Man RA, Kamar N, Durmaz G, de Bruijne J, Vanwolleghem T, et al. Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. J Viral Hepatitis. 2021;28(2):431\u20135.","journal-title":"J Viral Hepatitis"},{"issue":"5","key":"1321_CR84","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s15010-018-1168-7","volume":"46","author":"E Biliotti","year":"2018","unstructured":"Biliotti E, Franchi C, Spaziante M, Garbuglia AR, Volpicelli L, Palazzo D, et al. Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin. Infection. 2018;46(5):725\u20137.","journal-title":"Infection"},{"key":"1321_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104570","volume":"170","author":"T Nishiyama","year":"2019","unstructured":"Nishiyama T, Kobayashi T, Jirintai S, Nagashima S, Primadharsini PP, Nishizawa T, et al. Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro. Antiviral Res. 2019;170:104570.","journal-title":"Antiviral Res"},{"issue":"37","key":"1321_CR86","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.3748\/wjg.v26.i37.5543","volume":"26","author":"AT Aslan","year":"2020","unstructured":"Aslan AT, Balaban HY. Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol. 2020;26(37):5543\u201360.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1321_CR87","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/HEP.0000000000000430","volume":"78","author":"J Howell","year":"2023","unstructured":"Howell J, Seaman C, Wallace J, Xiao Y, Scott N, Davies J, et al. Pathway to global elimination of hepatitis B: HBV cure is just the first step. Hepatology (Baltimore, MD). 2023;78(3):976\u201390.","journal-title":"Hepatology (Baltimore, MD)"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01321-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:37:11Z","timestamp":1775104631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01321-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1321"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01321-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"27 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"He-ming Sun, Xing-yu Wang, Hong-qin Xu and Yan-hang Gao have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}